Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
MAP2K1 K57N Selumetinib lung adenocarcinoma sensitive detail...
PIK3CA H1047R Dactolisib lung adenocarcinoma sensitive detail...
PIK3CA H1047R Sirolimus lung adenocarcinoma no benefit detail...
FBXW7 R465H Temsirolimus lung adenocarcinoma sensitive detail...
FGFR3 - TACC3 Ponatinib lung adenocarcinoma sensitive detail...
FGFR3 - TACC3 Infigratinib lung adenocarcinoma sensitive detail...
ROS1 rearrange Crizotinib lung adenocarcinoma sensitive detail...
ERBB2 mutant Afatinib lung adenocarcinoma sensitive detail...
ALK rearrange ALK I1171T Alectinib lung adenocarcinoma resistant detail...
ALK rearrange ALK I1171T Crizotinib lung adenocarcinoma resistant detail...
Unknown unknown Nintedanib lung adenocarcinoma not applicable detail...
MAP2K1 Q56P Trametinib lung adenocarcinoma sensitive detail...
MAP2K1 Q56P Selumetinib lung adenocarcinoma sensitive detail...
MAP2K1 Q56P Refametinib lung adenocarcinoma sensitive detail...
MAP2K1 Q56P PD-0325901 lung adenocarcinoma sensitive detail...
BRAF mutant Trametinib lung adenocarcinoma sensitive detail...
NRAS mutant Trametinib lung adenocarcinoma resistant detail...
ABL1 R332W Imatinib lung adenocarcinoma sensitive detail...
ABL1 G321L Imatinib lung adenocarcinoma sensitive detail...
ABL1 T315I ABL1 R332W Imatinib lung adenocarcinoma resistant detail...
ABL1 R332W Dasatinib lung adenocarcinoma sensitive detail...
ABL1 G321L Dasatinib lung adenocarcinoma sensitive detail...
ABL1 T315I ABL1 R332W Dasatinib lung adenocarcinoma resistant detail...
IDH1 mutant Dasatinib lung adenocarcinoma resistant detail...
ERBB2 exon 20 ins Afatinib lung adenocarcinoma predicted - sensitive detail...
ERBB2 Y772_A775dup Afatinib lung adenocarcinoma no benefit detail...
ERBB2 G778_P780dup Afatinib lung adenocarcinoma predicted - sensitive detail...
FGFR1 positive AZD4547 + AZD8055 lung adenocarcinoma sensitive detail...
FGFR1 positive AZD4547 + Vistusertib lung adenocarcinoma sensitive detail...
FGFR1 positive AZD4547 + Sirolimus lung adenocarcinoma sensitive detail...
BRAF G469L Vemurafenib lung adenocarcinoma no benefit detail...
BRAF N581S PF-00477736 + PF3644022 lung adenocarcinoma predicted - sensitive detail...
ERBB2 L869R Lapatinib lung adenocarcinoma predicted - resistant detail...
ERBB2 M774delinsWLV Dacomitinib lung adenocarcinoma sensitive detail...
ERBB2 G778_P780dup Dacomitinib lung adenocarcinoma sensitive detail...
AKT1 E17K Capivasertib lung adenocarcinoma predicted - sensitive detail...
Unknown unknown Docetaxel + Nintedanib lung adenocarcinoma not applicable detail...
FGFR3 positive Rogaratinib lung adenocarcinoma predicted - sensitive detail...
BRAF G469A PLX8394 lung adenocarcinoma sensitive detail...
BRAF G466V PLX8394 lung adenocarcinoma sensitive detail...
BRAF V600E BRAF amp SCH772984 lung adenocarcinoma decreased response detail...
BRAF V600E BRAF amp Dabrafenib + SCH772984 + Trametinib lung adenocarcinoma sensitive detail...
ALK rearrange ALK G1123S Ceritinib lung adenocarcinoma predicted - resistant detail...
ALK rearrange ALK G1123S Alectinib lung adenocarcinoma predicted - sensitive detail...
EML4 - ALK ALK C1156Y ALK L1196M Crizotinib lung adenocarcinoma predicted - resistant detail...
FGFR1 amp PRN1371 lung adenocarcinoma sensitive detail...
Unknown unknown AC-93253 iodide + Gefitinib lung adenocarcinoma not applicable detail...
Unknown unknown JNJ-64041757 lung adenocarcinoma not applicable detail...
RET V804M RET M918T Alectinib lung adenocarcinoma resistant detail...
BRAF V600E NRAS Q61K Dabrafenib + Trametinib lung adenocarcinoma predicted - resistant detail...
ERBB2 exon 20 ins Dacomitinib lung adenocarcinoma predicted - sensitive detail...
ERBB2 amp Dacomitinib lung adenocarcinoma no benefit detail...
ERBB2 G776delinsVC Poziotinib lung adenocarcinoma predicted - sensitive detail...
ERBB2 Y772_A775dup Poziotinib lung adenocarcinoma predicted - sensitive detail...
ERBB2 E812K Poziotinib lung adenocarcinoma predicted - sensitive detail...
ERBB2 N813D Afatinib lung adenocarcinoma predicted - sensitive detail...
ERBB2 act mut Ado-trastuzumab emtansine lung adenocarcinoma predicted - sensitive detail...
ERBB2 G778_P780dup Ado-trastuzumab emtansine lung adenocarcinoma predicted - sensitive detail...
ERBB2 G776delinsVC Ado-trastuzumab emtansine lung adenocarcinoma predicted - sensitive detail...
ERBB2 V659E Ado-trastuzumab emtansine lung adenocarcinoma predicted - sensitive detail...
ERBB2 S310F ERBB2 amp Ado-trastuzumab emtansine lung adenocarcinoma predicted - sensitive detail...
ALK rearrange ALK L1152R Alectinib lung adenocarcinoma predicted - sensitive detail...
ALK rearrange ALK L1152R Ceritinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK L1196M Crizotinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK F1174L ALK G1269A Belizatinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK F1174L ALK D1203N ALK G1269A Ceritinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK L1256F Lorlatinib lung adenocarcinoma resistant detail...
EML4 - ALK ALK L1256F Alectinib lung adenocarcinoma sensitive detail...
EML4 - ALK ALK T1151K Crizotinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK T1151K Ceritinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK Crizotinib lung adenocarcinoma predicted - sensitive detail...
ALK rearrange ALK L1196M Crizotinib lung adenocarcinoma predicted - resistant detail...
ALK rearrange ALK L1196M ALK D1203N Ceritinib lung adenocarcinoma predicted - resistant detail...
ALK rearrange ALK L1196M ALK D1203N Lorlatinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK C1156Y ALK G1269A Lorlatinib lung adenocarcinoma unknown detail...
ALK rearrange ALK C1156Y Lorlatinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK C1156Y ALK G1269A Lorlatinib + Saracatinib lung adenocarcinoma sensitive detail...
ALK rearrange ALK C1156Y Lorlatinib + Saracatinib lung adenocarcinoma sensitive detail...
EML4 - ALK ALK E1154K ALK G1202R ALK I1268V Crizotinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK E1154K ALK G1202R ALK I1268V Ceritinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK G1202R Brigatinib lung adenocarcinoma predicted - resistant detail...
EML4 - ALK ALK T1151M ALK C1156Y ALK F1174L ALK G1202R ALK S1206F ALK G1269A Lorlatinib lung adenocarcinoma predicted - resistant detail...
ALK rearrange ALK G1269A Crizotinib lung adenocarcinoma predicted - resistant detail...
ALK rearrange ALK F1174L Ceritinib lung adenocarcinoma predicted - resistant detail...
RET rearrange Cabozantinib lung adenocarcinoma predicted - sensitive detail...
ERBB2 G776delinsVC Afatinib lung adenocarcinoma predicted - sensitive detail...
ERBB2 V777L Afatinib lung adenocarcinoma predicted - sensitive detail...
Unknown unknown ORCA-010 lung adenocarcinoma not applicable detail...
BRAF G464V Trametinib lung adenocarcinoma no benefit detail...
BRAF G466A Trametinib lung adenocarcinoma no benefit detail...
BRAF D594G Trametinib lung adenocarcinoma no benefit detail...
BRAF N581S Trametinib lung adenocarcinoma no benefit detail...
BRAF G466V Trametinib lung adenocarcinoma no benefit detail...
BRAF G469A Trametinib lung adenocarcinoma no benefit detail...
ERBB2 L755P Ado-trastuzumab emtansine lung adenocarcinoma no benefit detail...
ERBB2 G778_S779insCPG Ado-trastuzumab emtansine lung adenocarcinoma no benefit detail...
ERBB2 act mut Trastuzumab deruxtecan lung adenocarcinoma sensitive detail...
ERBB2 G778_P780dup Poziotinib lung adenocarcinoma predicted - sensitive detail...
ERBB2 G778_P780dup Pyrotinib lung adenocarcinoma predicted - sensitive detail...
ERBB2 G778_P780dup ERBB2 amp Pyrotinib lung adenocarcinoma predicted - sensitive detail...
ERBB2 G778_P780dup ERBB2 amp Dacomitinib lung adenocarcinoma predicted - sensitive detail...
ERBB2 G778_P780dup Afatinib + Cisplatin + Pemetrexed Disodium lung adenocarcinoma predicted - sensitive detail...
CDKN2A loss Palbociclib lung adenocarcinoma predicted - sensitive detail...
PIK3CA mutant Capivasertib lung adenocarcinoma no benefit detail...
AKT1 mutant Capivasertib lung adenocarcinoma no benefit detail...
EML4 - ALK Lorlatinib lung adenocarcinoma conflicting detail...
EML4 - ALK Alvocidib lung adenocarcinoma sensitive detail...
EML4 - ALK Dinaciclib lung adenocarcinoma sensitive detail...
EML4 - ALK Alvocidib + Crizotinib lung adenocarcinoma predicted - sensitive detail...
EML4 - ALK THZ1 lung adenocarcinoma sensitive detail...
ALK rearrange CT-707 lung adenocarcinoma predicted - sensitive detail...
ERBB2 G778_S779insCPG Bevacizumab + Pyrotinib lung adenocarcinoma predicted - sensitive detail...
STK11 mutant unspecified PD-1 antibody lung adenocarcinoma not predictive detail...
STK11 mutant unspecified PD-L1 antibody lung adenocarcinoma not predictive detail...
STK11 mutant N/A lung adenocarcinoma not applicable detail...
BRAF V600E Trametinib lung adenocarcinoma predicted - sensitive detail...
ALK rearrange Bevacizumab + Lorlatinib lung adenocarcinoma predicted - sensitive detail...
ERBB2 Y772_A775dup Ado-trastuzumab emtansine lung adenocarcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01579994 Phase I Crizotinib + Ganetespib Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers Completed USA 0
NCT01737502 Phase Ib/II Auranofin + Sirolimus Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer Recruiting USA 0
NCT01814553 Phase III Afatinib + Loperamide ADAM-Afatinib Diarrhea Assessment and Management Completed USA 0
NCT01877083 Phase II Lenvatinib Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung Completed USA 4
NCT01877811 Phase Ib/II RXDX-105 CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2 Completed USA 0
NCT01976741 Phase I Rogaratinib Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor Completed USA 6
NCT02185690 Phase I Binimetinib + Carboplatin + Pemetrexed Disodium A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung Active, not recruiting CAN 0
NCT02231164 Phase III Docetaxel Nintedanib LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research Terminated USA 2
NCT02264678 Phase Ib/II AZD6738 AZD6738 + Carboplatin AZD6738 + Durvalumab AZD6738 + Olaparib Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents Recruiting USA 3
NCT02285855 Phase II Metformin Metformin in Non Small Cell Lung Cancer (NSCLC) Terminated USA 0
NCT02450175 Phase I Letrozole Everolimus Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls Unknown status USA 0
NCT02450591 Phase I Erlotinib Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations Completed USA 0
NCT02466568 Phase Ib/II Nivolumab Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung Withdrawn 0
NCT02503358 Phase I Paclitaxel + Selumetinib Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer Completed USA 0
NCT02513667 Phase II Ceritinib Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma Active, not recruiting USA 0
NCT02705339 Phase II Rociletinib Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC) Withdrawn 0
NCT02759835 Phase II Osimertinib Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib Active, not recruiting USA 0
NCT02839681 Phase II Anetumab ravtansine Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma Terminated USA 0
NCT02864992 Phase II Tepotinib Tepotinib Phase II in Non-small Cell Lung Cancer (NSCLC) Harboring MET Alterations (VISION) Recruiting USA 14
NCT03076164 Phase Ib/II Erlotinib + Trametinib A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib Completed USA 0
NCT03102320 Phase I Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) Active, not recruiting USA | CAN 10
NCT03255083 Phase I DS-1205c + Osimertinib DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Active, not recruiting 1
NCT03371381 Phase Ib/II JNJ-64041757 + Nivolumab Nivolumab An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung Terminated USA 2
NCT03476681 Phase I NEO-201 QUILT-3.017: Study of NEO-201 in Solid Tumors Recruiting USA 0
NCT03696212 Phase Ib/II Grapiprant + Pembrolizumab Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma Terminated USA 0
NCT03704688 Phase Ib/II Ponatinib + Trametinib Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT03894618 Phase I SL-279252 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Recruiting USA | CAN 2
NCT03944772 Phase II Necitumumab + Osimertinib Osimertinib + Selpercatinib Alectinib + Osimertinib Carboplatin + Durvalumab + Pemetrexed Disodium Osimertinib + Savolitinib Gefitinib + Osimertinib Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (ORCHARD) Recruiting USA 7
NCT04145622 Phase Ib/II DS-7300a Study of DS-7300a in Participants With Advanced Solid Malignant Tumors Recruiting USA 1
NCT04180371 Phase Ib/II BT5528 + Nivolumab BT5528 Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression Recruiting USA 1
NCT04263090 Phase Ib/II Nivolumab + Rigosertib Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment Recruiting USA 0
NCT04300556 Phase Ib/II MORAb-202 A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FR alpha)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types Recruiting USA 0
NCT04424641 Phase Ib/II GEN1044 A Study on the Safety of GEN1044 (DuoBody-CD3x5T4) in Subjects With Malignant Solid Tumors Recruiting USA 3
NCT04545710 Phase II Abemaciclib + Osimertinib Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance Recruiting USA 0
NCT04557449 Phase I Letrozole + PF-07220060 Fulvestrant + PF-07220060 PF-07220060 Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4) Recruiting USA 0
NCT04682431 Phase I Pembrolizumab + PY159 PY159 A Phase 1a/1b First-In-Human (FIH) Study of PY159 in Subjects With Advanced Solid Tumors Recruiting USA 0